[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335051-105":59,"doc-detail-335051-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","myc-family-amplification-dictates-sensitivity-to-bet-bromodomain-protein-inhibitor-mivebresib-abbv075-in-small-cell-lung-cancer","MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer","","Small-cell lung cancer (SCLC) represents nearly 15% of lung cancers and typically responds initially to cisplatin/carboplatin plus etoposide before rapid relapse and limited second-line options. In SCLC tumors and human-derived cell lines, amplifications among MYC family members occur in a mutually exclusive manner, driving single-factor overexpression that is required for tumor growth. This study characterizes SCLC cell lines harboring MYC or MYCN amplification and shows superior sensitivity to the pan-BET bromodomain inhibitor mivebresib (ABBV075), while MYCL1-amplified or non-amplified MYC lines respond less. Silencing MYC and MYCN partially rescues cell lines from mivebresib antiproliferative effects, linking BET-pathway inhibition to MYC dependency. Genome-wide binding studies reveal unique enhancer and epigenetic preferences of MYC, MYCN, and MYCL1, implying chromatin landscapes establish distinct gene-expression programs that confer sensitivity to epigenetic inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/myc-family-amplification-dictates-sensitivity-to-bet-bromodomain-protein-inhibitor-mivebresib-abbv075-in-small-cell-lung-cancer/335051/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/myc-family-amplification-dictates-sensitivity-to-bet-bromodomain-protein-inhibitor-mivebresib-abbv075-in-small-cell-lung-cancer/335051.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role do MYC family amplifications play in small-cell lung cancer?","Question",{"text":112,"@type":113},"In many SCLC tumors and derived cell lines, amplification affects MYC family members (MYC, MYCN, or MYCL1) in a mutually exclusive way, leading to overexpression of a single MYC factor that supports tumor growth.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does mivebresib (ABBV075) affect SCLC cell lines with MYC family amplifications?",{"text":117,"@type":113},"SCLC cell lines harboring MYC and MYCN amplification exhibit superior sensitivity to the pan-BET bromodomain inhibitor mivebresib (ABBV075) compared with non-amplified or MYCL1-amplified counterparts.",{"name":119,"@type":110,"acceptedAnswer":120},"How do MYC and MYCN influence sensitivity to mivebresib?",{"text":121,"@type":113},"Silencing MYC or MYCN partially rescues MYC/MYCN-amplified SCLC cell lines from the antiproliferative effects of mivebresib, supporting a dependency link between MYC activity and drug response.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335051,1790745945,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer  \nJoshua P. Plotnik1, Zheng Zha2, Weiguo Feng2, Irene Lee3, Jacob Riehm3, Ryan A. McClure4, Stephanie Sandoval4, Tamar Uziel3, Erin Murphy2, Xin Lu2, and Lloyd T. Lam3  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Small-cell lung cancer (SCLC) accounts for nearly 15% of all\u003Cbr>lung cancers. Although patients respond to first-line therapy\u003Cbr>readily, rapid relapse is inevitable, with few treatment options in\u003Cbr>the second-line setting. Here, we describe SCLC cell lines har\u003Cbr>boring amplification of MYC and MYCN but not MYCL1 or non\u003Cbr>amplified MYC cell lines exhibit superior sensitivity to treatment\u003Cbr>with the pan-BET bromodomain protein inhibitor mivebresib\u003Cbr>(ABBV075) . Silencing MYC and MYCN partially rescued SCLC\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | cell lines harboring these respective amplifications from the\u003Cbr>antiproliferative effects of mivebresib. Further characterization of\u003Cbr>genome-wide binding of MYC, MYCN, and MYCL1 uncovered\u003Cbr>unique enhancer and epigenetic preferences.\u003Cbr>Implications: Our study suggests that chromatin landscapes can\u003Cbr>establish cell states with unique gene expression programs, con\u003Cbr>veying sensitivity to epigenetic inhibitors such as mivebresib. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nSmall-cell lung cancer (SCLC) accounts for nearly 15% of all lung cancers (1) and is established from basal lung neuroendocrine precursors upon inactivation of the p53 and RB1 tumor suppressor genes (2) . First-line therapy, cisplatin/carboplatin plus etoposide, often demonstrates partial response followed by rapid relapse (2) . The advanced stage of diagnosis and rapid progression of SCLC is responsible for poor 5-year survival (3) . Despite these clinical challenges, recent work characterizing the molecular and genetic landscapes has led to a greater understanding of key transcription factor drivers of molecular subtypes in SCLC, offering novel avenues for targeted therapeutic intervention (4) .  \nIn >20% of SCLC patient tumors and >50% of human-derived cell lines, an amplification event occurs in any of the three MYC transcription factors: MYC, MYCN, or MYCL1 (5–7) . These MYC family member amplification events occur in a mutually exclusive fashion and result in the overexpression of a single MYC transcription factor in tumors and cell lines. Further, MYC, MYCN, or MYCL1 expression is required for tumor growth in small-cell cancers. Previous efforts to identify the roles of MYC, MYCN, and MYCL1 have relied on transcriptome analysis of cell lines harboring  \n1Oncology Discovery Research, AbbVie Inc., North Chicago, Illinois. 2Genomic Research Center, AbbVie Inc., North Chicago, Illinois. 3Precision Medicine, Translational Oncology, AbbVie Inc., North Chicago, Illinois. 4Physical Chemist","cbCaihJ4tSJFNt7Q","https://ap.wps.com/l/cbCaihJ4tSJFNt7Q","pdf",3581265,"English","# Introduction\n## MYC family amplifications in SCLC\n## Clinical challenge and need for targeted interventions\n## Rationale for BET bromodomain inhibition and mivebresib","[{\"question\":\"What role do MYC family amplifications play in small-cell lung cancer?\",\"answer\":\"In many SCLC tumors and derived cell lines, amplification affects MYC family members (MYC, MYCN, or MYCL1) in a mutually exclusive way, leading to overexpression of a single MYC factor that supports tumor growth.\"},{\"question\":\"How does mivebresib (ABBV075) affect SCLC cell lines with MYC family amplifications?\",\"answer\":\"SCLC cell lines harboring MYC and MYCN amplification exhibit superior sensitivity to the pan-BET bromodomain inhibitor mivebresib (ABBV075) compared with non-amplified or MYCL1-amplified counterparts.\"},{\"question\":\"How do MYC and MYCN influence sensitivity to mivebresib?\",\"answer\":\"Silencing MYC or MYCN partially rescues MYC/MYCN-amplified SCLC cell lines from the antiproliferative effects of mivebresib, supporting a dependency link between MYC activity and drug response.\"}]","MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer | PDF",1790009486,25]